Answers are grounded in this paper and cite their sources.
Identifies mutated JAK kinases and deregulated STAT activity as therapeutic targets in cutaneous T-cell lymphoma, suggesting new treatment avenues.
The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are starting to be identified. Recent evidence suggests that disturbances in specific intracellular signaling pathways, such as RAS-MAPK, TCR-PLCG1-NFAT and JAK-STAT, can play an essential role in the
No takes yet. Share an insight, caveat, or question.
Pérez et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: